X0306 4 2020-07-23 0 0001693011 Inozyme Pharma, Inc. INZY 0001640073 Edwards Martin C/O INOZYME PHARMA, INC. 321 SUMMER STREET, SUITE 400 BOSTON MA 02210 1 0 0 0 Stock Option (right to buy) 16.00 2020-07-23 4 A 0 9367 0.00 A 2030-07-22 Common Stock 9367 9367 D The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest as to 100% of the shares on July 23, 2021, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. The Reporting Person is employed on a part-time basis as a senior partner at Novo Holdings A/S ("Novo"), and is expected to retire from Novo in the fall of 2020. Novo does not have any beneficial or pecuniary interest in the securities held by the Reporting Person, and the Reporting Person does not have any beneficial or pecuniary interest in the securities held by Novo. /s/ Stephen Basso, as attorney-in-fact for Martin Edwards 2020-07-24